Abiraterone CAS:154229-19-3

Usage: Indicatur usus in compositione cum valium pro curatione metastaticae castrationis repugnantis cancer prostatae.

Abiraterone medicamentum adhibetur cum valium in metastatica castratione repugnante cancer prostatae (formerly hormone repugnans vel hormone-refractior prostatae cancer) — i.e., prostatae cancer privatio vel curatio cum androgen non respondet antiandrogens. It is formulated as the prodrug abiraterone acetate and marketed under the trade name Zytiga. Cadila Pharmaceuticals has recently started marketing Abiraterone acetate under the trade name Abretone.

After an expedited six-month review, abiraterone was approved by the U.S. Food and Drug Administration (FDA) in April 2011. In Phase III trials, it extended median survival to 14.8 months versus 10.9 months placebo, and the trial was stopped because of the successful outcome.

Indicatur usus in compositione cum valium pro curatione metastaticae castrationis repugnantis cancer prostatae. It has received FDA (28 April 2011), EMA (23 September 2011), MHRA (5 September 2011) and TGA (1 March 2012) approval for this indication. In Australia it is covered by the Pharmaceutical Benefits Scheme when being used to treat castration-resistant prostate cancer and given in combination with prednisone/prednisolone (subject to the conditions that the patient is not currently receiving chemotherapy, is either resistant or intolerant of docetaxel, has a WHO performance status of <2, and his disease has not since become progressive since treatment with PBS-subsidised abiraterone has commenced).